CN108135892A - 用于治疗癌症的mdm2抑制剂的给药方案 - Google Patents

用于治疗癌症的mdm2抑制剂的给药方案 Download PDF

Info

Publication number
CN108135892A
CN108135892A CN201680061650.4A CN201680061650A CN108135892A CN 108135892 A CN108135892 A CN 108135892A CN 201680061650 A CN201680061650 A CN 201680061650A CN 108135892 A CN108135892 A CN 108135892A
Authority
CN
China
Prior art keywords
days
compound
salt
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680061650.4A
Other languages
English (en)
Chinese (zh)
Inventor
席奈奇亚契
蔡胜力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to CN202110980773.0A priority Critical patent/CN113521069A/zh
Publication of CN108135892A publication Critical patent/CN108135892A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680061650.4A 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案 Pending CN108135892A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110980773.0A CN113521069A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245632 2015-10-23
PCT/JP2016/081975 WO2017069289A1 (en) 2015-10-23 2016-10-21 Dosage regimen of mdm2 inhibitor for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110980773.0A Division CN113521069A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Publications (1)

Publication Number Publication Date
CN108135892A true CN108135892A (zh) 2018-06-08

Family

ID=57349101

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680061650.4A Pending CN108135892A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案
CN202110980773.0A Pending CN113521069A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110980773.0A Pending CN113521069A (zh) 2015-10-23 2016-10-21 用于治疗癌症的mdm2抑制剂的给药方案

Country Status (8)

Country Link
US (3) US20180296547A1 (enExample)
EP (1) EP3364972A1 (enExample)
JP (4) JP6855472B2 (enExample)
KR (1) KR20180064540A (enExample)
CN (2) CN108135892A (enExample)
HK (1) HK1253098A1 (enExample)
TW (3) TW202332444A (enExample)
WO (1) WO2017069289A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6823587B2 (ja) * 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
IL310121A (en) * 2021-08-09 2024-03-01 Boehringer Ingelheim Int A preparation for oral administration that includes an MDM2-antagonist for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635473A (zh) * 2011-03-10 2014-03-12 第一三共株式会社 二螺吡咯烷衍生物
WO2015108175A1 (en) * 2014-01-14 2015-07-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
CN104812757A (zh) * 2012-09-06 2015-07-29 第一三共株式会社 二螺吡咯烷衍生物的晶体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2644649C (en) * 2006-03-22 2014-06-17 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
EP2788004B1 (en) * 2011-12-07 2019-07-03 Duke University Methods of identifying and using mdm2 inhibitors
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
JP6368311B2 (ja) * 2013-09-04 2018-08-01 第一三共株式会社 スピロオキシインドール誘導体の製造方法
ES2968789T3 (es) * 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
EP3364972A1 (en) * 2015-10-23 2018-08-29 Daiichi Sankyo Company, Limited Dosage regimen of mdm2 inhibitor for treating cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635473A (zh) * 2011-03-10 2014-03-12 第一三共株式会社 二螺吡咯烷衍生物
CN104812757A (zh) * 2012-09-06 2015-07-29 第一三共株式会社 二螺吡咯烷衍生物的晶体
WO2015108175A1 (en) * 2014-01-14 2015-07-23 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张如明编著: "《软组织肉瘤现代外科治疗》", 28 February 2010, 天津科学技术出版社 *

Also Published As

Publication number Publication date
US20180296547A1 (en) 2018-10-18
TW201722427A (zh) 2017-07-01
US20190201386A1 (en) 2019-07-04
EP3364972A1 (en) 2018-08-29
WO2017069289A1 (en) 2017-04-27
TW202332444A (zh) 2023-08-16
JP6855472B2 (ja) 2021-04-07
TWI806822B (zh) 2023-07-01
KR20180064540A (ko) 2018-06-14
US11058673B2 (en) 2021-07-13
JP2024164122A (ja) 2024-11-26
JP2018531273A (ja) 2018-10-25
US20220071975A1 (en) 2022-03-10
JP2021098750A (ja) 2021-07-01
JP2023025214A (ja) 2023-02-21
CN113521069A (zh) 2021-10-22
HK1253098A1 (zh) 2019-06-06
TW202515561A (zh) 2025-04-16
JP7192011B2 (ja) 2022-12-19

Similar Documents

Publication Publication Date Title
JP7192011B2 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
JP7668777B2 (ja) 癌治療
CN107921006A (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
CN110831580A (zh) 用于治疗癌症的组合疗法
JP6995058B2 (ja) （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
JP2018531273A6 (ja) がんを治療するためのｍｄｍ２阻害剤の投与計画
TW202421145A (zh) Kras g12c抑制劑之給藥方案
KR20210003780A (ko) Axl 키나제 억제제 및 그의 용도
KR20230015888A (ko) 사시투주맙 고비테칸 요법에 대한 바이오마커
US11224608B2 (en) Compounds and methods for treating cancer
CN115867669A (zh) 监测kras突变的方法
Parisi et al. Current evidence and future perspectives about the role of PARP inhibitors in the treatment of thoracic cancers
JP7571024B2 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
US20250186446A1 (en) Organic compounds
US20220323443A1 (en) Combination therapy for cancer treatment
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2025207705A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
WO2024263963A2 (en) Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
WO2024263972A2 (en) Compositions comprising antineoplastons and methods of treating uncommon cancers
WO2024263966A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
CN119818513A (zh) 治疗儿科患者的癌症的方法
HK40031775A (en) Compounds and methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180608

RJ01 Rejection of invention patent application after publication